Literature DB >> 29312689

Locally advanced non-small cell lung cancer treatment: another step forward.

Pier Luigi Filosso1, Francesco Guerrera1, Paolo Olivo Lausi1, Enrico Ruffini1.   

Abstract

Entities:  

Year:  2017        PMID： 29312689      PMCID： PMC5757015          DOI： 10.21037/jtd.2017.11.103

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117.

Authors:  Jeffrey D Bradley; Jennifer Moughan; Mary V Graham; Roger Byhardt; Ramaswamy Govindan; Jack Fowler; James A Purdy; Jeff M Michalski; Elizabeth Gore; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

2.  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

Authors:  David E Gerber; James J Urbanic; Corey Langer; Chen Hu; I-Fen Chang; Bo Lu; Benjamin Movsas; Robert Jeraj; Walter J Curran; Jeffrey D Bradley
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

5.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.

Authors:  A Aupérin; C Le Péchoux; J P Pignon; C Koning; B Jeremic; G Clamon; L Einhorn; D Ball; M G Trovo; H J M Groen; J A Bonner; T Le Chevalier; R Arriagada
Journal:  Ann Oncol       Date:  2006-03       Impact factor: 32.976

Review 6.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Authors:  Pasi A Jänne; Jeffrey A Engelman; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

7.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Authors:  Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam
Journal:  Lancet Oncol       Date:  2015-02-20       Impact factor: 41.316

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread.

Authors:  Antoine Legras; Pierre Mordant; Alex Arame; Christophe Foucault; Antoine Dujon; Françoise Le Pimpec Barthes; Marc Riquet
Journal:  Ann Thorac Surg       Date:  2014-02-26       Impact factor: 4.330

Review 10.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.